This makes retatrutide one of the strongest incretins around, affecting both how quickly the stomach empties and how our brains control hunger and feeling full
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet
No regulatory authority has approved it
Many patients experience improvements in: Metabolic health: Lower blood sugar levels and improved insulin sensitivity
Jeon, C
Our breakthrough patch is a non-invasive, pain-free alternative to traditional GLP-1 injectionsproviding powerful support for weight management, blood sugar stabilization, and type 2 diabetes treatment, without the discomfort or inconvenience of needles